Biosense Webster, a Johnson & Johnson company has published data in JAMA, showing that the patients with Atrial Fibrillation, who were treated with the Navistar Thermocool Catheter, demonstrated better outcomes at one year compared to those receiving drug therapy.
In addition, the patients treated with catheter ablation reported markedly fewer symptoms and substantially improved quality of life.
The Navistar Thermocool Catheter ablation group also demonstrated a safety profile with no device-related serious adverse events such as death, heart attack, stroke, cerebrovascular accident, heart block or atrial perforation within seven days post ablation. The incidence of treatment related adverse events measured at 30 days in the Thermocool Catheter ablation group was observed to be approximately half that in the AAD group (5% vs 9%) and there was no clinically significant pulmonary vein stenosis in patients receiving ablation.
The Navistar Thermocool Catheter is an ablation catheter approved by the FDA for the treatment of drug refractory recurrent symptomatic paroxysmal AFib when used with Carto Navigation Systems.
According to the study, at one year, 66% of patients treated with catheter ablation remained free from documented symptomatic AFib, compared to 16% of patients treated with medical therapy, also commonly referred to as anti-arrhythmic drugs or AADs.